RondelO RondelO - the first medical stopcock designed for sequential intraveneous infusion of incompatible drugs
- Coordinator
- Cyto365 AB, Sweden
- Runs
- 1 November 2022 to 30 April 2025
- Status
- Finished
- EU funding
- €1.9m
- Total cost
- €2.8m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190103560
What the project is doing
In the project's own words, from its summary on CORDIS.
CYTO365 is developing RondeO® - a revolutionary medical stopcock to be used with intravenous drug administration sets (IV sets). RondelO® is the first medical device that allows for a sequential intravenous administration of up to 6 drugs with the neutral saline in between the drugs. RondelO® aids the nurse to administer drugs to the patient safely and correctly, by letting only one drug pass at a time. It solves the problem of serious side effects caused by drug incompatibility by eliminating human error and unwanted parallel infusion and thereby increases patient safety.
Moreover, RondelO® is easy to use (minimal training required), safe for the user (Closed System Valve (CSV) minimizes hazardous drug expose for the nurse), customizable (different configurations with 2, 4 or 6 drug inlets with or without CSV available) and time-efficient (all drugs are connected to IV set at the beginning of the procedure).
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Cyto365 AB | Hoganas | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI